Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
- Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on the signing of the final license and supply agreement
- Mithra is eligible to receive a total of EUR 2.05 million sales-related milestones, along with tiered double-digit royalties on annual net sales and payments at signature of the license agreement and for regulatory milestones
- DONESTA® to target an addressable menopause market in Israel of ~900,000 women aged between 45 and 641
Liege, Belgium, 21 December 2023 - 17:45 CET - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces the signing of a binding Head of Terms (HoT) agreement for the commercialization of DONESTA® in Israel with Rafa Laboratories LTD, an Israeli pharmaceutical company. DONESTA® is Mithra's investigational, next generation hormone therapy medicine containing estetrol (E4) for the treatment of the symptoms of menopause.
Rafa Laboratories will have the exclusive commercial rights for DONESTA® in Israel and the Palestinian Territories on the signing of the final license and supply agreement - planned in Q1 2024.
Mithra is eligible to receive a total of EUR 2.05 million sales-related milestones, along with tiered double-digit royalties on annual net sales.
David Horn Solomon, CEO of Mithra stated, "We are thrilled that Mithra and Rafa Laboratories will work together to offer DONESTA® to women who suffer from the symptoms of menopause. We look forward to working closely with Rafa Laboratories to support its success in delivering differentiated efficacy, safety, and convenience to a market of hundreds of thousands of women."
Amir Levin, CEO of Rafa, commented, "We are excited to cooperate with Mithra on this new product which will enable Rafa Laboratories to add to its Women's Health portfolio. We are pleased to offer this next generation, orally administered estetrol-based hormone therapy product candidate to the Israeli market. It's innovative nature and the prospect it offers to women suffering from the symptoms of menopause can be a game-changer."
For more information, please contact:
| Mithra Pharmaceuticals SA Alex Sokolowski, PhD Head of IR & Communications investorrelations@mithra.com +32 (0)4 349 28 22 | Frédérique Depraetere Communications Director info@mithra.com +32 (0)4 349 28 22 |
About Mithra
Mithra Pharmaceuticals SA
ESTELLE® and DONESTA® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Subscribe to our mailing list on investors.mithra.com (https://investors.mithra.com/en/contact/subscribe) to receive press releases by email or follow us on social media: Linkedin (https://www.linkedin.com/company/1456363/) • X (https://twitter.com/mithrapharma) • Facebook (https://www.facebook.com/mithrapharmaceuticals/) |
1 World Health Organization data, 2021
Attachment
- 2023-12-21_Mithra_Press-Release_Rafa-Israel-HoT-Agreement_FR (https://ml-eu.globenewswire.com/Resource/Download/ab045d34-e915-423f-b5c7-b691f571b74e)
